Evolus Turns the Page: Portfolio Strategy and Skin Quality Arrive as Market Recovers
The inflection point
Evolus reported its strongest quarter as a public company, beating its own expectations and raising full-year guidance. Revenue grew 21% year-over-year to $84.1 million, with global toxin revenue of $75.2 million and injectable hyaluronic acid gel revenue of $8.9 million. Importantly, the company delivered its third consecutive quarter of positive adjusted EBITDA, a clean break from the cash-burn history of the last several years.
As CEO David Moatazedi put it, “The second quarter represents a meaningful inflection point for Evolus.” — David Moatazedi, President and Chief Executive Officer · 2026-08-05 That inflection is visible in the company’s own price action: after a prolonged drawdown that saw the stock fall roughly 78% from its 2018 peak, the last 90 days show a 96% rally, suggesting the market is beginning to price in the operational turnaround.
The catalyst is not a single product launch but a deliberate strategic pivot. Evolus is no longer the single-product toxin company it was two years ago. It has built a portfolio spanning neurotoxins, hyaluronic acid fillers, and now a third vertical—skin quality. The quarter’s biggest announcement was a licensing agreement with Swiss-based IPSY for exclusive U.S. rights to ProFuelo, a skin-quality hyaluronic acid gel that has no direct U.S. competitor. Moatazedi described the product as “not adding volume. it is changing the overall texture of the skin.” — David Moatazedi, President and Chief Executive Officer · 2026-08-05 This is a fundamentally different mechanism from traditional fillers—one that relies on a patented thermal process rather than cross-linking.
With the addition of ProFuelo, Evolus is expanding into a new third injectable aesthetics vertical of skin quality.
This move is company-unique. While “skin quality” is a buzzword in consumer aesthetics, it did not appear in the global keyword trajectory for the quarter, and it is new to Evolus’s own earnings vocabulary—the keyword ranked #1 in the company’s last quarter with a momentum surge. The company plans to file a PMA with the FDA, with approval anticipated around 2030. Rui Avelar, Chief Medical Officer, explained the clinical rationale: “This is a different way of actually creating a gel. … it actually hydrates the skin. Internally.” — Rui Avelar C.CFP Dip.SportMed · 2026-08-05
The filler market rebounds – and Evolus is ahead of it
The second quarter’s strength also reflects a turn in the underlying market, something management had been cautious about in prior calls. In the Q4 2025 call, Moatazedi said, “we do believe that the filler market will start to recover towards the latter part of the year.” — David Moatazedi, President and Chief Executive Officer · 2026-03-04 That recovery now appears to be arriving. On this call, he noted the U.S. neurotoxin market grew at a “faster than expected” mid-single-digit rate, while the hyaluronic acid gel market returned to positive growth after two consecutive years of declines. He also highlighted a GLP-1 tailwind: “we are the only hyaluronic acid that has mention of weight loss in our label.” — David Moatazedi, President and Chief Executive Officer · 2026-08-05 The company is capitalizing on this with co-branded media targeting GLP-1 patients, a strategy that helped drive market share gains during the quarter.
The portfolio rebate program, which bundles Jeuveau and Evolysse, is showing early traction. Roughly 70% of accounts participating in the growth bundle purchased Evolysse, versus about 25% of the overall customer base. This is the kind of cross-sell that was absent when Evolus was a one-product company. As Moatazedi said, the company is on track for both Evolysse and international business to each contribute more than 10% of total revenue this year.
The financial trajectory is fundamentally different
The improvement is visible in the fundamentals. Total revenue has climbed from near-zero in 2018 to over $84 million in a single quarter in 2026, and management raised the full-year 2026 guide to $330–$337 million. Gross margin, which was 68% in Q2 (69% adjusted), benefited from a tariff refund, and the company reaffirmed its long-term targets of $450–$500 million in revenue and 13–15% adjusted EBITDA by 2028.
Perhaps more notable is the change in capital discipline. For the first time in its history, Evolus is talking about funding transformative investments out of cash flow rather than equity. CFO Tatjana Mitchell said the company has “ample financial flexibility to support our commercial priorities.” — Tatjana Mitchell, Chief Financial Officer · 2026-08-05 The balance sheet still shows net debt of -$110 million, but the trajectory—three consecutive positive EBITDA quarters—has changed the conversation. The stock’s 96% rally in the last 90 days is a direct response to this shift.
The contrast with the recent past is stark. As recently as December 2025, management was guiding to low-single-digit market growth and a filler market that was still declining. Today, they are raising guidance on the back of accelerating demand and a portfolio that extends into skin quality and international markets. The ProFuelo deal, along with the expansion of the Symatese partnership into Canada, Australia, and New Zealand, signals that Evolus is being seen as a credible partner for aesthetic innovation, not just a generic toxin producer.
There are still risks: ProFuelo faces a long regulatory path, the filler market recovery is only six months old, and GLP-1 competition could shift consumer appetite. But for the first time in years, the evidence points to a company that has found a durable growth formula. The second quarter of 2026 may be remembered as the moment Evolus became a multi-product, multi-geography platform rather than a single brand with a distant profitability goal.